Ascendis Pharma reports Q1 2026 results today against a backdrop of strengthening short-side sentiment — but options traders are firmly in the bull camp.
The standout signal heading into the print is the options market. The put/call ratio has drifted toward its 52-week low, hitting 0.32 on Monday before settling at 0.34 — near the least defensive reading of the past year. With calls dominating, the options market is expressing genuine confidence in the near-term outcome, not bracing for a miss. The stock reinforces that picture: ASND added 4.7% on Wednesday and 7.1% on the week to close at $235.90, well ahead of most biotech peers heading into the report.
The short side tells a different story. The ORTEX short score has climbed sharply — from 41.8 on April 28 to 58.8 by May 5, a 40% jump in under two weeks. That acceleration suggests growing conviction among short sellers even as the stock rallied. Borrow costs have also ticked up, rising roughly 33% over the past week to 0.98% APR, though that absolute level remains modest. Availability is loose at around 269% of short interest, meaning the lending pool is far from stretched. Shorts are building positions, but there is no squeeze dynamic in place.
The fundamental debate centers on pipeline execution versus competitive pressure. Bulls point to Ascendis's TransCon platform as a genuine differentiator, with TransCon CNP in achondroplasia and the already-launched Yorvipath for adult growth hormone deficiency providing a commercial proof of concept. The EPS forward momentum score ranks in the 85th percentile — well above the sector median — suggesting analysts have been steadily upgrading their earnings outlook. The analyst consensus is a buy, with a mean price target near $254, implying around 7.5% upside from current levels. Bears counter that clinical and regulatory execution risk remains material, that pricing pressure is a structural overhang across the biopharmaceutical space, and that competition in the endocrine therapy market is intensifying. The RSI reading of 38 also flags that momentum, despite this week's bounce, has been weak over the medium term.
Valuation gives bulls some comfort. The EV/EBITDA multiple has compressed roughly 10% over the past month to 19.6x, and the PE of 43x, while elevated, has been stable — the stock is not obviously more stretched than it was. What today's print tests is whether Yorvipath's commercial uptake and TransCon CNP's trial progress are tracking well enough to justify that multiple at a moment when short sellers have quietly been adding conviction.
See the live data behind this article on ORTEX.
Open ASND on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
